Business
Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates
VAV1-directed MRT-6160 program advancing toward multiple Phase 2 studies, enabled by Phase 1 SAD/MAD study data supporting broad potential application in immune-mediated diseases MRT-2359 Phase 1/2 study data demonstrate encouraging signals of clinical response in heavily pretreated castration-resistant prostate cancer patients resistant to AR therapy; additional results expected in H2 2025 MRT-8102, a NEK7-directed molecular glue degrader targeting diseases driven by IL-1β and the NLRP3 inflamm
About this update from Monte Rosa Therapeutics, Inc.
[{"type":"image","alt":"Monte Rosa Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Monte Rosa Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":82,"url":"https://media.zenfs.com/en/globenewswire.com/c99f028be58427489eba79299e175651"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/OzxkCVdlx.rHq4uLVBRKVA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c99f028be58427489eba79299e175651","width":300,"height":82}},"lazy":false},{"type":"text","content":"VAV1-directed MRT-6160 program advancing toward multiple Phase 2 studies, enabled by Phase 1 SAD/MAD study data supporting broad potential application in immune-mediated diseases","length":178,"tagName":"p"},{"type":"text","content":"MRT-2359 Phase 1/2 study data demonstrate encouraging signals of clinical response in heavily pretreated castration-resistant prostate cancer patients resistant to AR therapy; additional results expected in H2 2025","length":214,"tagName":"p"},{"type":"text","content":"MRT-8102, a NEK7-directed molecular glue degrader targeting diseases driven by IL-1β and the NLRP3 inflammasome, on track for IND filing in H1 2025","length":152,"tagName":"p"},{"type":"text","content":"Cyclin E1 (CCNE1) and CDK2-directed MGD programs for the treatment of CCNE1-driven solid tumors and ER+ breast cancer advancing toward the clinic; IND submission anticipated in 2026","length":186,"tagName":"p"},{"type":"text","content":"Strong cash position expected to fund operations into 2028 through multiple anticipated proof-of-concept clinical readouts","length":122,"tagName":"p"},{"type":"text","content":"BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today reported business highlights and financial results for the first quarter ended March 31, 2025.","length":290,"tagName":"p"},{"type":"text","content":"“We’ve made significant progress across our entire portfolio in the development of our only-in-class and first-in-class molecular glue degrader therapeutics, targeting diseases poorly addressed by conventional pharmaceutical approaches,” said Markus Warmuth, M.D., Chief Executive Officer of Monte Rosa Therapeutics. “As highlighted in our rece...